COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,762 Articles (22,502 medRxiv, 8,260 bioRxiv)

Most recent first Previous |  Page 3028: Articles 30271-30280  | Next

Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China
Wang, Y., Jiang, W., He, Q., Wang, C., Wang, B., Zhou, P., Dong, N., Tong, Q.
10.1101/2020.03.06.20032342 — Posted: 2020-03-12 Discussion: Onsite
Revealing the influence of national public health policies for the outbreak of the SARS-CoV-2 epidemic in Wuhan, China through status dynamic modeling
qiu, t., Xiao, H.
10.1101/2020.03.10.20032995 — Posted: 2020-03-12
Discovery of a 382-nt deletion during the early evolution of SARS-CoV-2
Su, Y., Anderson, D., Young, B., Zhu, F., Linster, M., Kalimuddin, S., Low, J., Yan, Z., Jayakumar, J., Sun, L., Yan, G., Mendenhall, I., Leo, Y.-S., Lye, D., Wang, L.-F., Smith, G.
10.1101/2020.03.11.987222 — Posted: 2020-03-12 Discussion: Onsite
Novel and potent inhibitors targeting DHODH, a rate-limiting enzyme in de novo pyrimidine biosynthesis, are broad-spectrum antiviral against RNA viruses including newly emerged coronavirus SARS-CoV-2
Xiong, R., Zhang, L., Li, S., Sun, Y., Ding, M., Wang, Y., Zhao, Y., Wu, Y., Shang, W., Jiang, X., Shan, J., Shen, Z., Tong, Y., Xu, L., Chen, Y., Liu, Y., Zou, G., Lavillete, D., Zhao, Z., Wang, R., Zhu, L., Xiao, G., Lan, K., Li, H., Xu, K.
10.1101/2020.03.11.983056 — Posted: 2020-03-12 Discussion: Onsite
Rigidity, normal modes and flexible motion of a SARS-CoV-2 (COVID-19) protease structure.
Wells, S. A.
10.1101/2020.03.10.986190 — Posted: 2020-03-12 Discussion: Onsite
A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19
Ge, Y., Tian, T., Huang, S., Wan, F., Li, J., Li, S., Yang, H., Hong, L., Wu, N., Yuan, E., Cheng, L., Lei, Y., Shu, H., Feng, X., Jiang, Z., Chi, Y., Guo, X., Cui, L., Xiao, L., Li, Z., Yang, C., Miao, Z., Tang, H., Chen, L., Zeng, H., Zhao, D., Zhu, F., Shen, X., Zeng, J.
10.1101/2020.03.11.986836 — Posted: 2020-03-12
The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15
Matsuyama, S., Kawase, M., Nao, N., Shirato, K., Ujike, M., Kamitani, W., Shimojima, M., Fukushi, S.
10.1101/2020.03.11.987016 — Posted: 2020-03-12 Discussion: Onsite
A human monoclonal 1 antibody blocking SARS-CoV-2 infection
Wang, C., Li, W., Drabek, D., Okba, N. M. A., van Haperen, R., Osterhaus, A. D. M. E., van Kuppeveld, F. J. M., Haagmans, B. L., Grosveld, F., Bosch, B.-J.
10.1101/2020.03.11.987958 — Posted: 2020-03-12 Discussion: Onsite
The SARS-CoV-2 exerts a distinctive strategy for interacting with the ACE2 human receptor
Brielle, E. S., Schneidman, D., Linial, M.
10.1101/2020.03.10.986398 — Posted: 2020-03-12
Development of Reverse Transcription Loop-mediated Isothermal Amplification (RT-LAMP) Assays Targeting SARS-CoV-2
Park, G.-S., Ku, K., Beak, S.-H., Kim, S. J., Kim, S. I., Kim, B.-T., Maeng, J.-S.
10.1101/2020.03.09.983064 — Posted: 2020-03-12

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).